CMAC installation aims to revolutionise drugs development data access
One of the UK’s leading centres for pharmaceutical manufacturing and digital production methods says new capabilities will allow it to significantly overcome a key manual limitation on accelerating medicines development and output.
Strathclyde University’s CMAC (Continuous Manufacturing and Advanced Crystallisation) centre has invested in Plvs Ultra’s Enterprise Intelligence Engine.
This uses knowledge graph technology capable of making semantic connections across previously disconnected data systems.
Plvs Ultra CEO and co-founder Patrick Hyett said the tool could overcome the complexity of “connecting and interrogating years of manufacturing science data across continuous processes, chemistry, and scale-up”.
“Without the ability to semantically connect that data, the complexity becomes a barrier, one that manual processes and conventional data tools simply cannot overcome,” he stated.
The Scottish centre specialises in CMC (chemistry, manufacturing and controls), during which laboratory processes are scaled for commercial use.
Each new molecule that enters the pipeline must be treated as a fresh start with manufacturing processes that will take it from laboratory to commercial production unable to tap into knowledge from previous work, costing time and resources.
Processes can be notoriously difficult to replicate with poor quality deviations impacting the equivalent of 25–40% of total sales revenue, outlined CMAC.
Furthermore, production downtime caused by investigation delays can delay subsequent regulatory filings by up to 12 months, with the result that millions of pounds worth of medicines prevented from distribution.
Deployment of the technology is a cornerstone of CMAC’s £33m UK-RPIF CMAC Data Lab project being designed as a pilot for placing data intelligence infrastructure at the heart of UK pharmaceutical manufacturing.
Plvs Ultra’s Hyett said transformation of data from a compliance documentation requirement into an active resource can be delivered within 12 weeks, compared with traditional enterprise data projects that might take years.
CMAC director, professor Alastair Florence commented: “As we undertake increasingly ambitious research projects for our pharma members and with our academic and technology partners, it is essential that we can manage complex, multi-source data while leveraging decades of accumulated expertise.”
Related Content
London Lab Live: A capital investment
Launched last year as part of the Future Labs’ stable, the London show looks here to stay. One year on, …
From Injection to Ingestion: Can yeast make vaccines more accessible?
Vilnius University reports how its Life Sciences (VU LSC) Center and the U.S. National Cancer Institute are exploring yeast-based oral vaccines …
Pistoia to publish guide to pharma firm social media listening
The Pistoia Alliance is for the first time engaging health patients in its research, in order to aid its new …
